These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 31175323)
1. Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML. Karjalainen R; Liu M; Kumar A; He L; Malani D; Parsons A; Kontro M; Kallioniemi O; Porkka K; Heckman CA Leukemia; 2019 Oct; 33(10):2548-2553. PubMed ID: 31175323 [No Abstract] [Full Text] [Related]
2. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML. Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848 [TBL] [Abstract][Full Text] [Related]
3. A synthetic lethal approach targeting mutant isocitrate dehydrogenase in acute myeloid leukemia. Verma A; Steidl U Nat Med; 2015 Feb; 21(2):113-4. PubMed ID: 25654599 [No Abstract] [Full Text] [Related]
4. Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance. Liu F; Zhao Q; Su Y; Lv J; Gai Y; Liu S; Lin H; Wang Y; Wang G Exp Hematol; 2022 Jan; 105():39-49. PubMed ID: 34767916 [TBL] [Abstract][Full Text] [Related]
5. Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment. Chen X; Glytsou C; Zhou H; Narang S; Reyna DE; Lopez A; Sakellaropoulos T; Gong Y; Kloetgen A; Yap YS; Wang E; Gavathiotis E; Tsirigos A; Tibes R; Aifantis I Cancer Discov; 2019 Jul; 9(7):890-909. PubMed ID: 31048321 [TBL] [Abstract][Full Text] [Related]
6. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models. Garg R; Allen KJH; Dawicki W; Geoghegan EM; Ludwig DL; Dadachova E Cancer Med; 2021 Feb; 10(3):1128-1140. PubMed ID: 33347715 [TBL] [Abstract][Full Text] [Related]
7. Targeting S100A9 protein affects mTOR-ER stress signaling and increases venetoclax sensitivity in Acute Myeloid Leukemia. Fan R; Satilmis H; Vandewalle N; Verheye E; De Bruyne E; Menu E; De Beule N; De Becker A; Ates G; Massie A; Kerre T; Törngren M; Eriksson H; Vanderkerken K; Breckpot K; Maes K; De Veirman K Blood Cancer J; 2023 Dec; 13(1):188. PubMed ID: 38110349 [TBL] [Abstract][Full Text] [Related]
8. IDH1/2 mutations and BCL-2 dependence: an unexpected Chink in AML's armour. Pronier E; Levine RL Cancer Cell; 2015 Mar; 27(3):323-5. PubMed ID: 25759018 [TBL] [Abstract][Full Text] [Related]
13. Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM. Huemer F; Melchardt T; Jansko B; Wahida A; Jilg S; Jost PJ; Klieser E; Steiger K; Magnes T; Pleyer L; Greil-Ressler S; Rass C; Greil R; Egle A Eur J Haematol; 2019 May; 102(5):437-441. PubMed ID: 30725494 [TBL] [Abstract][Full Text] [Related]
14. CRISPR screen of venetoclax response-associated genes identifies transcription factor ZNF740 as a key functional regulator. Zhang L; Zhou X; Aryal S; Veasey V; Zhang P; Li FJ; Luan Y; Bhatia R; Zhou Y; Lu R Cell Death Dis; 2024 Aug; 15(8):627. PubMed ID: 39191721 [TBL] [Abstract][Full Text] [Related]
15. 5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis. Jin S; Cojocari D; Purkal JJ; Popovic R; Talaty NN; Xiao Y; Solomon LR; Boghaert ER; Leverson JD; Phillips DC Clin Cancer Res; 2020 Jul; 26(13):3371-3383. PubMed ID: 32054729 [TBL] [Abstract][Full Text] [Related]
16. The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells. Nechiporuk T; Kurtz SE; Nikolova O; Liu T; Jones CL; D'Alessandro A; Culp-Hill R; d'Almeida A; Joshi SK; Rosenberg M; Tognon CE; Danilov AV; Druker BJ; Chang BH; McWeeney SK; Tyner JW Cancer Discov; 2019 Jul; 9(7):910-925. PubMed ID: 31048320 [TBL] [Abstract][Full Text] [Related]
17. Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner. Huang S; Li C; Zhang X; Pan J; Li F; Lv Y; Huang J; Ling Q; Ye W; Mao S; Huang X; Jin J Mol Oncol; 2020 Oct; 14(10):2560-2573. PubMed ID: 32519423 [TBL] [Abstract][Full Text] [Related]
19. Discovery of a Covalent Inhibitor That Overcame Resistance to Venetoclax in AML Cells Overexpressing BFL-1. Lou J; Zhou Q; Lyu X; Cen X; Liu C; Yan Z; Li Y; Tang H; Liu Q; Ding J; Lu Y; Huang H; Xie H; Zhao Y J Med Chem; 2024 Jul; 67(13):10795-10830. PubMed ID: 38913996 [TBL] [Abstract][Full Text] [Related]